Autopsy report · NCT01942083

A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to Investigate Safety and Tolerability of OPB(Otsuka Pharmaceutical Biwa)-111077 in Subjects With Advanced HCC(Hepatocellular Carcinoma)

“Company decision”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 3 years 1 month before it stopped.
• 33 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Korea Otsuka Pharmaceutical Co., Ltd.

Sponsor type

Industry

Conditions

Advanced Hepatocellular Carcinoma

Interventions

OPB-111077

Participants

33

Sites

1

Countries

South Korea

Trials that died the same way

• 3D011-08 Monotherapy in Subjects With Advanced Solid Tumors
  “Company's decision” (97% match in meaning)
• Study of AROSOD-1 in Adult Participants With Amyotrophic Lateral Sclerosis (ALS)
  “Company business decision” (92% match in meaning)
• A Study of HTD1801 in Adolescents With Primary Sclerosing Cholangitis (PSC)
  “Corporate decision” (90% match in meaning)
• A Study of JNJ-75105186 in Healthy Japanese and Chinese Participants
  “Business Decision” (83% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.